OBJECTIVE: The soluble Fms-like @entity4149 kinase 1 (sFlt-1)/ @entity7309 ( @entity7309 ) ratio has been introduced as a biomarker for diagnosing @entity1468 ( @entity1468 ) and the prediction of adverse pregnancy outcome. In a cohort of pregnant @entity1 with @entity1468 or at high risk of @entity1468 , the additive value of the sFlt-1/ @entity7309 ratio for diagnosing @entity1468 and prediction of adverse pregnancy outcomes was investigated. DESIGN AND METHOD: From September 2011 until August 2013 @entity1 with suspected or confirmed clinical @entity1468 were recruited at the Erasmus MC. At time of admission, blood for measurement of sFlt-1 and @entity7309 was obtained. A sFlt-1/ @entity7309 ratio of >85 was considered suggestive for @entity1468 . Clinical characteristics and pregnancy outcomes were retrieved from medical records. The clinical diagnosis of @entity1468 was made based on the ISSHP criteria, whereas the fullPIERS definition was used for the rating of adverse pregnancy outcomes. RESULTS: A total of 96 @entity1 were included. Of the @entity1 , 53 (55%) met the clinical criteria of @entity1468 at time of blood sampling. In 11% of these @entity1 (n=6) the ratio was<85 (false-negative), whereas in 14% (n=6) of @entity1 without clinical @entity1468 the ratio was >85 (false positive), resulting in positive and negative predictive values of 89% and 86% respectively. Three @entity1 without clinical @entity1468 , but with a positive ratio, developed superimposed @entity1468 and 2 developed an adverse pregnancy outcome. In 2 of the 6 @entity1 with clinical @entity1468 but a negative ratio, an adverse pregnancy outcome was encountered. Using a binary regression model with adjustment for gestational age < 34 weeks, clinical @entity1468 was associated with a 9 times increased risk for an adverse outcome, while this was 29 times for an elevated ratio (P=0.036). CONCLUSIONS: The additive value of an increased ratio for diagnosing @entity1468 is limited since most @entity1 with clinical @entity1468 also have a positive ratio. An elevated ratio is superior to the clinical diagnosis of @entity1468 for predicting an adverse pregnancy outcome.

8C.01: SFLT-1 AND XXXX MEASUREMENTS AND THEIR RATIO FOR THE DIAGNOSIS AND PROGNOSIS OF PREECLAMPSIA IN A HIGH-RISK COHORT.

@entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity4149 :: ('D014443', 'Chemical') :: ['tyrosine'] @entity7309 :: ('5228', 'Gene') :: ['placental growth factor', 'PlGF'] @entity1468 :: ('MESH:D011225', 'Disease') :: ['preeclampsia', 'PE']
@entity7309 :: (5228,Gene) :: ['PLGF']
